当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

Abstract：

:Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60, NOMO-1, NB4, NKM-1, K562, Daudi, and the multidrug-resistant sublines, NOMO-1/ADR and NB4/MDR, was investigated by cell cycle distribution and morphology. These studies were done by a video-microscopic system, DNA fragmentation, dye exclusion and 3H-thymidine uptake after analysis of CD33, CD34, P-glycoprotein (P-gp), multidrug resistance (MDR)-associated protein and lung-related protein on these cells. A dose-dependent, selective cytotoxic effect of CMA-676 was observed in cell lines that expressed CD33, and was dependent on the amount of CD33 and the proliferative speed of the cells. Sensitive cells were temporally arrested at the G2/M phase before undergoing morphological changes. CMA-676 is not effective on P-gp-expressing multidrug-resistant sublines compared with parental cell lines. MDR modifiers, MS209 and PSC833, restored the cytotoxic effect of CMA-676 in P-gp-expressing sublines. CMA-676 is a promising agent in the treatment of patients with AML that expresses CD33. The combined use of CMA-676 and MDR modifiers may increase the selective cytotoxic effect in multidrug-resistant AML.

journal_name

Leukemia

journal_title

Leukemia

authors

Naito K,Takeshita A,Shigeno K,Nakamura S,Fujisawa S,Shinjo K,Yoshida H,Ohnishi K,Mori M,Terakawa S,Ohno R

doi

10.1038/sj.leu.2401851

subject

Has Abstract

pub_date

2000-08-01 00:00:00

pages

1436-43

issue

8

eissn

0887-6924

issn

1476-5551

journal_volume

14

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

    abstract：:The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Hanenberg H,Baumann M,Quentin I,Nagel G,Grosse-Wilde H,von Kleist S,Göbel U,Burdach S,Grunert F

    更新日期：1994-12-01 00:00:00

  • Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!

    abstract：:Mobilizing bone cells to the head, astutely referred to as 'bonehead' therapeutic approach, represents a major discipline of regenerative medicine. The last decade has witnessed mounting evidence supporting the capacity of bone marrow (BM)-derived cells to mobilize from BM to peripheral blood (PB), eventually finding ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2011.167

    authors： Borlongan CV

    更新日期：2011-11-01 00:00:00

  • The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice.

    abstract：:Hematopoietic stem cells are identified based on their functional ability to migrate via the blood circulation of transplanted recipients, to home to the host bone marrow and to durably repopulate this organ with high levels of maturing myeloid and lymphoid cells. While a small pool of undifferentiated stem cells with...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2402684

    authors： Lapidot T,Kollet O

    更新日期：2002-10-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract：:Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.283

    authors： Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期：2011-03-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract：:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.93

    authors： Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期：2014-10-01 00:00:00

  • Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

    abstract：:Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.170

    authors： Visconte V,Avishai N,Mahfouz R,Tabarroki A,Cowen J,Sharghi-Moshtaghin R,Hitomi M,Rogers HJ,Hasrouni E,Phillips J,Sekeres MA,Heuer AH,Saunthararajah Y,Barnard J,Tiu RV

    更新日期：2015-01-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract：:This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2017.327

    authors： Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期：2018-04-01 00:00:00

  • Targeting MYC in multiple myeloma.

    abstract：:Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0036-x

    authors： Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

    更新日期：2018-06-01 00:00:00

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    abstract：:Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0734-z

    authors： Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

    更新日期：2020-04-01 00:00:00

  • Heterogeneity of VH-JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL.

    abstract：:Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402234

    authors： Moreira I,Papaioannou M,Mortuza FY,Gameiro P,Palmisano GL,Harrison CJ,Prentice HG,Mehta AB,Hoffbrand AV,Foroni L

    更新日期：2001-10-01 00:00:00

  • Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.

    abstract：:Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA librar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402551

    authors： Rowntree C,Duke V,Panayiotidis P,Kotsi P,Palmisano GL,Hoffbrand AV,Foroni L

    更新日期：2002-07-01 00:00:00

  • CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.

    abstract：:Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.1

    authors： Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

    更新日期：2011-05-01 00:00:00

  • Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis.

    abstract：:Bone mineral density (BMD) and biochemical markers of bone metabolism were analyzed in 67 adults with ALL (n = 27), AML (n = 14), MDS (n = 6) and CML (n = 20) before and after allogeneic stem cell transplantation (SCT). Median age was 36 years (17-56). Twenty-six out of 53 patients (49%) had osteopenia and osteoporosi...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2402264

    authors： Massenkeil G,Fiene C,Rosen O,Michael R,Reisinger W,Arnold R

    更新日期：2001-11-01 00:00:00

  • Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients.

    abstract：:The main reason for the unfavorable clinical outcome of BCR-ABL1-positive acute lymphoblastic leukemia (ALL) is genetic instability. However, how normal B-cell precursors acquire the genetic changes that lead to transformation has not yet been completely defined. We investigated the expression of the activation-induce...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.197

    authors： Iacobucci I,Lonetti A,Messa F,Ferrari A,Cilloni D,Soverini S,Paoloni F,Arruga F,Ottaviani E,Chiaretti S,Messina M,Vignetti M,Papayannidis C,Vitale A,Pane F,Piccaluga PP,Paolini S,Berton G,Baruzzi A,Saglio G,Baccar

    更新日期：2010-01-01 00:00:00

  • High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.

    abstract：:We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404404

    authors： Skärby TV,Anderson H,Heldrup J,Kanerva JA,Seidel H,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

    更新日期：2006-11-01 00:00:00

  • Natural killer-cell malignancies: diagnosis and treatment.

    abstract：:Natural killer (NK)-cell malignancies are uncommon diseases. Previously known as polymorphic reticulosis or angiocentric T-cell lymphomas, they are classified by the World Health Organization as NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia. They are prevalent in Asia and South America, but exceptiona...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2403955

    authors： Kwong YL

    更新日期：2005-12-01 00:00:00

  • IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.

    abstract：:Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Dilloo D,Hanenberg H,Lion T,Burdach S

    更新日期：1995-03-01 00:00:00

  • Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.

    abstract：:Mutations of the GATA1 gene on chromosome X have been found in almost all cases of transient myeloproliferative disorder and acute megakaryoblastic leukemia (AMKL) accompanying Down syndrome (DS). Although most GATA1 mutations lead to the expression of GATA1s lacking the N-terminal activation domain, we recently found...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404223

    authors： Xu G,Kanezaki R,Toki T,Watanabe S,Takahashi Y,Terui K,Kitabayashi I,Ito E

    更新日期：2006-06-01 00:00:00

  • Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles.

    abstract：:A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401608

    authors： Uozumi K,Otsuka M,Ohno N,Moriyama T,Suzuki S,Shimotakahara S,Matsumura I,Hanada S,Arima T

    更新日期：2000-01-01 00:00:00

  • Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.

    abstract：:Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia unspecified (one case) or s-myelodysplastic syndrome (five cases) following treatment for a primary malignancy. B...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401021

    authors： Secker-Walker LM,Moorman AV,Bain BJ,Mehta AB

    更新日期：1998-05-01 00:00:00

  • Establishment and characterization of a murine megakaryoblastic cell line growing in protein-free culture (L8057Y5).

    abstract：:A murine megakaryoblastic cell line growing in protein-free culture (L8057Y5) was established from an experimentally induced murine leukemia (MK8057). Most of the Y5 cells were small and blast-like, with 2-4N in DNA content. Also, large cells possessing a lobulated nucleus characteristic of megakaryocytes, which showe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sasaki H,Kajigaya Y,Hirabayashi Y,Funabiki T,Inoue T,Yokota T,Ikuta K,Arai K,Matsuyama S

    更新日期：1991-05-01 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract：:It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402013

    authors： Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期：2001-02-01 00:00:00

  • Myeloid surface antigen expression in adult acute lymphoblastic leukemia.

    abstract：:The expression of myeloid surface markers was investigated in 41 cases of untreated adult acute lymphoblastic leukemia (ALL). Nineteen cases (46%) reacted with at least one myeloid monoclonal antibody (CD15 in 16 cases, CD13 in 10 cases, CD14 in five cases, and CD33 in four cases). Double-staining confirmed the coexpr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Guyotat D,Campos L,Shi ZH,Charrin C,Treille D,Magaud JP,Fiere D

    更新日期：1990-09-01 00:00:00

  • Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

    abstract：:Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41375-020-0758-4

    authors： Kayser S,Rahmé R,Martínez-Cuadrón D,Ghiaur G,Thomas X,Sobas M,Guerci-Bresler A,Garrido A,Pigneux A,Gil C,Raffoux E,Tormo M,Vey N,de la Serna J,Salamero O,Lengfelder E,Levis MJ,Fenaux P,Sanz MA,Platzbecker U,Schlen

    更新日期：2020-09-01 00:00:00

  • Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.

    abstract：:This review will summarize the rationale for pursuing investigations into the use of retinoids for pediatric patients with cancer, describe the phase I results of all-trans-retinoic acid (ATRA) in children, and discuss the results of a series of preclinical and clinical pharmacokinetic studies of ATRA. The prognosis f...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Adamson PC

    更新日期：1994-01-01 00:00:00

  • Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

    abstract：:After accounting for misdiagnosis and treatment effect, allele-specific (AS)-PCR detects the JAK2V617F mutation in >95% of polycythemia vera (PV) patients. Using database inquiry, we identified 6 of a total 220 cases with PV that were JAK2V617F-negative (prevalence=3%). Of these, five cases ( approximately 80%) were f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404810

    authors： Pardanani A,Lasho TL,Finke C,Hanson CA,Tefferi A

    更新日期：2007-09-01 00:00:00

  • Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

    abstract：:Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.313

    authors： Kumar SK,Dispenzieri A,Lacy MQ,Gertz MA,Buadi FK,Pandey S,Kapoor P,Dingli D,Hayman SR,Leung N,Lust J,McCurdy A,Russell SJ,Zeldenrust SR,Kyle RA,Rajkumar SV

    更新日期：2014-05-01 00:00:00

  • A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

    abstract：:Cladribine has been reported to have little activity in fludarabine- refractory chronic lymphocytic leukemia (CLL). We sought to determine whether resistance to therapy with cladribine in fludarabine-refractory CLL patients represented primary drug resistance or the inability to tolerate the myelosuppression associate...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.leu.2402752

    authors： Byrd JC,Peterson B,Piro L,Saven A,Vardiman JW,Larson RA,Schiffer C

    更新日期：2003-02-01 00:00:00

  • Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation.

    abstract：:Cyclooxygenase (COX)-1 or -2 and specific prostaglandin (PG) synthases catalyze the formation of various PGs. We investigated the expression and activity of COX-1 and -2 during granulocyte-oriented maturation induced by all-trans-retinoic acid (ATRA) of NB4 cells, originated from a human acute promyelocytic leukemia (...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403407

    authors： Rocca B,Morosetti R,Habib A,Maggiano N,Zassadowski F,Ciabattoni G,Chomienne C,Papp B,Ranelletti FO

    更新日期：2004-08-01 00:00:00

  • Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.

    abstract：:The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

    更新日期：1993-08-01 00:00:00